Nanotechnology and Drug Delivery: Recent Applications and Future Challenges by Tohidi Moghadam, Tahereh
Tahereh Tohidi Moghadam







•	 Advances in nanotechnology have revolutionized fabrication and development of novel materials with 
diverse theranostic applications. 
•	 Gold nanoparticles (GNPs) have been nominated as promising candidates in delivery of protein and 
peptide drugs.
•	 A deep understanding of biological responses to bare nanoparticles and their complex form is a prerequisite 
to produce low risk hybrid nanocarrier systems.  
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ABSTRACT
Today, nanotechnology has paved the way for developing a new generation of delivery 
systems for potential drugs, proteins, peptides, and genes of interest. This effort reviews 
a couple of recent reports on application of gold nanoparticles in protein/peptide delivery, 
with a glance at toxicological aspects of nanoparticles and potential challenges in the 
upcoming future.
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Introduction 
Recent reports have witnessed unprecedented growth 
of research and applications in nanoscience and 
nanotechnology (Huang et al., 2011). There is increasing 
optimism that nanotechnology will bring remarkable 
advances in diagnosis and treatment of different diseases 
(Peer et al., 2007; Godin et al., 2010; Brambilla et al., 
2011; Huang et al., 2011). So far, a variety of biomedical 
applications has been proposed for nanomaterials including 
drug delivery, in vitro and in vivo molecular diagnostics, 
nutraceuticals, biomedical imaging, biocompatible 
materials of improved properties (Figuerola et al. 2010; 
Huang and El-Sayed 2010; Jayakumar et al., 2010; Thanh 
et al. 2010; Lev Dykman et al., 2012; Tohidi Moghadam 
and Ranjbar, 2015; Mohseni et al. 2016), and the list 
could go on and on.
Drug delivery and related pharmaceutical development 
in the context of nanomedicine is considered as science 
and technology of hybrid systems at nanometer scale, 
consisting of a pharmaceutically active ingredient 
(Duncan, 2005). However, at times, it is possible to 
formulate the candidate drug at nanoscale, without 
using nanoparticles or nanomaterials as the carrier 
system (Duncan, 2005). Either in the complex form or 
nanoformulation, the overall system plays a critical role 
in developing functions related to treating, preventing 
or simultaneous diagnosis and treatment of diseases, i.e. 
theranostics (Jong and Borm, 2008). The primary goals of 
nanobiotechnologists in drug delivery research are drug 
targeting	and	delivery	with	high	specificity,	low	toxicity	
(meanwhile maintaining therapeutic effects), more safety 
and biocompatibility, and also development of new safe 
medicines.
To design new materials of therapeutic characteristics 
and appropriate carrier systems for successful delivery 
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surface charge, morphology, etc. (Chakraborty et al., 
2011; Tohidi Moghadam et al., 2011; Tohidi Moghadam 
et al., 2012; Dai et al., 2016).
Based on evidences of fruitful applications of 
nanotechnology in medicine, this mini review has 
focused on a number of recent reports on utilization of 
gold nanoparticles, as promising candidates in delivery of 
protein and peptide drugs, as well as an overview of other 
nanomaterials in the context of drug delivery systems and 
their future challenges.
Percutaneous delivery of peptide drugs
Huang et al. have reported an interesting nanoscale 
interfacial phenomenon mediated by gold nanoparticles 
(GNPs). Co-administration of protein drug with 5 
nm GNPs enabled skin permeation and percutaneous 
delivery of the drug (Huang et al., 2010). The researchers 
suggested that the phenomenon might occur due to the 
nano-bio interaction with skin lipids and the consequent 
induction of transient and reversible openings in 
the stratum corneum. They also noticed that upon 
simultaneous utilization of GNPs, the protein drugs could 
penetrate the skin barrier and migrate into the deep layers. 
Therefore, co-administration of a potential drug with 
the skin-permeable GNPs can mediate proteins across 
the skin barrier. The results of this effort highlighted a 
simple, yet effective method of overcoming the skin 
barrier for percutaneous protein drug delivery (Fig. 1). 
to the targeted area, a number of factors still make 
the achievements challenging. Such issues comprise 
knowledge of (i) drug incorporation and release, (ii) 
formulation stability and shelf life (iii) biocompatibility, 
(iv) biodistribution, targeting, and (v) functionality 
(Borm and Muller-Schulte, 2006; Jong and Borm, 
2008). Moreover, when nanoparticles are used as carrier 
systems, possible adverse effects might occur, which 
should be carefully considered. Sometimes the residual 
material itself might induce toxicity after delivering the 
drug to the sight of interest. In this respect, biodegradable 
nanoparticle, as well as biocompatible one with a limited 
life span (as long as therapeutically needed) would be 
optimal (Jong and Borm, 2008). Another important issue 
in the context of drug/protein/peptide/gene delivery by 
nanoparticles has risen due to the fact that nanoparticles 
might induce a number of alterations in the structure of 
biomolecules. Once the structure of biomolecule has 
undergone irreversible structural/conformational changes, 
it might severely lose its function prior to reaching the 
targeted area for desired therapeutic action. So far, results 
of many reports have encouraged possibility of using 
nanoparticle based drug delivery systems. On the other 
hand, fundamental investigations on the structure and 
function of biomolecules with various nanoparticles as 
carrier candidates are scarce (Tohidi Moghadam et al., 
2011).	 It	 is	also	worth	noting	 that	 the	final	 fate	of	nano	
drug	delivery	systems	with	fruitful	function	and	efficacy	
critically depends upon the type of nanoparticle, its size, 
Figure 1.Transcutaneous antigen delivery mediated by GNPs (Huang et al., 2010).
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More importantly, the method is considered to be a non 
invasive strategy for developing novel vaccine delivery 
techniques. With topical co-administration of antigens 
and gold nanoparticles, robust immune responses were 
shown in the tested animals. As a consequence, achieving 
a needleless and self-administrable transcutaneous 
vaccination can be expected in the upcoming future.
Peptide cancer vaccines delivery                  
It has been noticed that gold nanoparticles are promising 
vehicles for cancer immunotherapy, with demonstrated 
efficacy	in	immune	delivery	and	innate	cell	stimulation.	
Nevertheless, their potency for delivery of peptide 
cancer vaccines and in vivo applications needs to 
be deeply assessed. Almedia et al. assumed that the 
immune distribution and adjuvant qualities of GNPs 
could facilitate delivery of the ovalbumin (OVA) 
peptide antigen and the CpG adjuvant, enhancing their 
therapeutic effect in a B16-OVA tumor model (Almedia 
et al., 2015). As anticipated, GNPs-mediated delivery 
of OVA (GNPs-OVA) and CpG (GNPs-CpG) increased 
the	efficacy	of	both	agents,	with	 strong	antigen-specific	
responses. Furthermore, the researchers found  that using 
GNPs-OVA	 delivery	 without	 CpG	 was	 sufficient	 to	
promote	significant	antigen-specific	responses,	leading	to	
subsequent anti-tumor activity and prolonged survival in 
both prophylactic and therapeutic in vivo tumor models. 
Such	 enhanced	 therapeutic	 efficacy	might	 be	 attributed	
to the adjuvant effect of peptide coated GNPs, as the 
complex	 system	 induced	 inflammatory	 cytokine	 release	
when cultured with bone marrow dendritic cells (Almedia 
et	al.,	2015).	The	significant	therapeutic	effect	of	GNPs-
mediated peptide delivery system (without the use of 
adjuvant) evidenced that AuNPs are effective peptide 
vaccine carriers with possibility of decreasing adjuvant 
doses for safer vaccination (Almedia et al., 2015).
Nanoparticle mediated laser transfection of 
proteins     
Molecular medicine has faced many challenges for 
efficient	and	targeted	delivery	of	proteins	into	mammalian	
cells. To overcome the problems, nanotechnology is 
proposed to have a key solution. Nowadays, nanoparticle-
laser interactions are widely used in cell manipulation 
processes. In the light of large cross section of 
plasmonic nanoparticles and ability to strongly absorb 
electromagnetic radiation at a characteristic wavelength, 
Heinemann et al. presented a new protein transfection 
technique via laser scanning of cells incubated with gold 
nanoparticles (Heinemann et al., 2014). The plasmonic 
effects of the gold nanoparticles upon absorption of laser 
radiation induced a transient permeabilization of the 
cellular membrane, allowing proteins to enter the cell. 
The researchers tested this strategy to monitor possibility 
of	 delivering	 green	 fluorescent	 protein	 (GFP)	 into	
mammalian cells. Heinemann et al. noticed that GFP was 
delivered	with	an	efficiency	of	43%,	maintaining	a	high	
level of cell viability. 
Furthermore, functional delivery of an apoptosis 
mediating	 protein	 i.e.	 Caspase	 3	 was	 tested	 in	 several	
cellular assays (Heinemann et al., 2014). The researchers 
claimed that compared to conventional protein transfection 
techniques such as microinjection, gold nanoparticle 
mediated laser transfection enables high-throughput 
transfection of about 10000 cells per second. Moreover, 
a	 well-defined	 point	 in	 time	 of	 delivery	 is	 guaranteed,	
providing detailed temporal analysis of cellular pathways 
and	protein	trafficking	(Heinemann	et	al.,	2014).
Functional nano-capping agents for targeting 
drug delivery              
Recently, Ganchao Chen et al. designed a novel stimuli 
responsive drug delivery system, using mesoporous silica 
nanoparticles	(MSNs),	benefiting	from	its	high	porosity,	
good tunability and ease of functionalization (Chen et 
al., 2016). End-capped MSNs has the potential to display 
“zero premature release” prior to reaching target tissues 
or cells, whereas it shows controlled drug release upon 
exposure	 to	 specific	 internal/external	 stimuli.	 So	 far,	
numerous MSN-based controlled release systems have 
been developed using variety of pore-blocking agents, 
such as macromolecules, nucleic acid, polymers, inorganic 
nanoparticles (INPs), proteins, or peptides. Once the drug 
carrier reaches the target, control of the payload release is 
usually	achieved	via	specific	stimuli,	either	internal	stimuli	
such as the presence of certain biomolecules (e.g. ATP or 
enzymes), redox potential, pH, or external stimuli such 
as light, temperature, ultrasound, etc. (Chen et al., 2016). 
The researchers designed a hierarchically constructed pH-
responsive nano-carrier utilizing peptide functionalized 
gold nanoparticles as the gate-keeper for targeting drug 
delivery (Fig. 2). They used gold nanoparticles as MSNs’ 
pore capping agent due to good biocompatibility, facile 
modification	 with	 thiol	 containing	 ligands	 or	 peptides,	
and desirable physicochemical features for constructing 
multi-functional nano-carriers (Chen et al., 2016). The 
researchers functionalized MSNs via a pH sensitive 
linker with negative charge, which degrades in the acidic 
environment in endo/lysosome. On the other hand, GNPs 
were coated with oligo-Lysine containing peptides to hold 
positive charge, and RGD peptide to enhance the targeting 
efficiency	towards	cancer	cells	(Chen	et	al.,	2016).	Under	
neutral condition, the pores of MSNs were decorated and 
capped by a layer of gold nanoparticles and peptide to 
inhibit	premature	 leakage.	Upon	endocytosis,	 the	acidic	
environment of the endo/lysosome (pH 4.0-6.0) induced 
rapid hydrolysis of the linker, resulting in a charge 
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reversal of the MSNs and removal of the nano-capping 
agent and release of the entrapped drug (Doxorubicin). 
The incorporation of RGD peptide facilitated targeting 
delivery	to	αvβ3	integrin overexpressing cancer cells (Chen 
et al., 2016). The system designed in this report can serve 
as	 a	 platform	 for	 developing	diversified	multifunctional	
nanocomposites with variety of functional inorganic 
nanoparticles and bioactive peptides (Chen et al., 2016).
Future challenges
So far, a considerable amount of data has been released 
on the toxicity of engineered NPs, such as fullerenes 
(Yamakoshi	 et	 al.,	 2003;	 Oberdörster	 2004;	 Sayes	 et	
al., 2005; Lovern and Klaper, 2006), carbon nanotubes 
(Shvedova	et	al.,	2003;	Lam	et	al.,	2004;	Warheit	et	al.,	
2004; Sayes et al., 2006; Monteiro-Riviere et al., 2005), 
dendrimers (Svenson and Tomalia, 2005; Duncan and 
Izzo, 2005), quantum dots (Hardman, 2006; Cho et al., 
2007), and  (Derfus et al. 2004; Hoshino et al., 2004; 
Kirchner et al., 2005; Hoshino et al., 2007).  
Nevertheless, this data is mainly based on a limited 
category	 of	 nanoparticles	 (Oberdörster,	 2004).	 In	 most	
studies, the nanoparticles have been used as a model of 
ambient air particle toxicity. One of the more general 
conclusions is that nanoparticles tend to be more toxic 
than larger particles with the same chemical composition. 
For nanoformulations used in drug delivery systems, most 
reports have mainly focused on taking proper strategies 
to reduce toxicity of the incorporated drug; whereas the 
possible toxicity of the nanocarrier itself has not been 
considered. In particular, it is possible that residues of 
a typical treatment may harbor potential local and/or 
systemic toxic responses.
The use of Nanotechnology in developing a new 
generation of drug delivery system is set to spread rapidly. 
The pharmaceutical industry has been seriously seeking 
novel nanoformulations strategies, using nanoparticles 
to reduce toxicity and side effects of the conventional 
drugs. Fortunately, it has been realized that nanocarrier 
systems themselves might impose unknown risks to 
the patient and severely interrupt the overall diagnostic 
and therapeutic procedures. The types of hazards that 
could be introduced by nanoparticles are still beyond 
our knowledge border. Very little is known about the 
fundamentals of the interaction of nanoparticles with 
living cells, organs, and organisms. A deep understanding 
of biological responses to bare nanoparticles and their 
complex form is a prerequisite to develop low risk drug 
nanocarrier systems in the future. 
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